No registrations found.
ID
Source
Brief title
Health condition
Acute Myeloid leukemia
Acute myeloide leukemie
Sponsors and support
Dept. of Hematologie
University Medical Center Groningen
P.O. Box 30.001
9700 RB Groningen
The Netherlands
Intervention
Outcome measures
Primary outcome
1. Expression of multidrug-resistance genes, nuclear receptors and in vitro susceptibity for 6-MP;
2. Changes in the lymphoid compartment during treatment with 6-MP;
3. HLA-type;
4. Clinical response on treatment with 6-MP.
Secondary outcome
N/A
Background summary
30%-40% of the patients with acute myeloid leukemia (AML) demonstrate a clinical response upon treatment with 6-mercaptopurine (6-MP). So far no predictive parameters have been identified that recognize this subgroup of patients, but preliminary data suggest an immunological mediated effect that might be operative in addition to a cytostatic effect.
Study objective
N/A
Study design
N/A
Intervention
Peripheral blood and bone marrow cells will be collected before and during treatment with 6-MP.
P.O. Box 30001
E. Vellenga
Groningen 9700 RB
The Netherlands
+31 (0)50 3612354
e.vellenga@int.umcg.nl
P.O. Box 30001
E. Vellenga
Groningen 9700 RB
The Netherlands
+31 (0)50 3612354
e.vellenga@int.umcg.nl
Inclusion criteria
1. Age >18 years;
2. Diagnosed with (relapsing) AML and not eligible for intensive chemotherapy.
Exclusion criteria
Ineligible or not willing to perform the proposed tests.
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| NTR-new | NL1701 |
| NTR-old | NTR1811 |
| Other | UMCG Groningen : |
| ISRCTN | ISRCTN wordt niet meer aangevraagd |